bioAffinity Technologies, Inc. (NASDAQ:BIAF)

US · Delayed Price · Currency is USD

7.70-1.73 (-18.35%)

Market Cap	3.23M-90.1%
Revenue (ttm)	5.90M-23.2%
Net Income	-15.19M-29.9%
EPS	-120.15+61.2%
Shares Out	418.87K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	741,620
Open	8.45
Previous Close	9.43
Day's Range	7.39 - 8.59
52-Week Range	4.56 - 109.35
Beta	n/a
Analysts	Hold
Price Target	n/a
Earnings Date	Nov 18, 2026

Full Chart

Alerts Compare

––Not scored

BIAF Insider Score

No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.

See stocks that are scored

About BIAF

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Address

3300 Nacogdoches Road, San Antonio, TX, 78217, US

Market Cap

3 million

Employees

Industrial Classification

Medical - Diagnostics & Research

1 Day

-18.35%

5 Days

+28.12%

1 Month

+28.33%

6 Months

-81.20%

1 Year

-90.07%

$BIAF stock is featured in our Insider Trades datasets.

→ All Stock Lists

Whale Activity →

Recently reported changes in BIAF holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BIAF's directors and management

No SEC Form 4 activity for BIAF in the last 5 quarters.

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BIAF Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New BIAF patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BIAF from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in BIAF

ETF	Est. Holding Size
VXFVanguard Extended Market ETF	$16.88K

Estimated from each fund’s disclosed top holdings × AUM

BIAF Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

No Insider Score for BIAF yet — no open-market insider buys or sells in the last 90 days.

Bull Case vs Bear Case

AI-generated from BIAF’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys

Sells

Buy Value

Distinct Buyers

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.